Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272)

A Phase I clinical trial of 1-beta-D-arabinofuranosyl-5-azacytosine (ara-AC or fazarabine) given as a 72-h continuous infusion on a 21-day cycle was conducted in 27 adult patients with refractory cancer. The major toxicity was reversible granulocytopenia and thrombocytopenia. Dose-limiting toxicity...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 50; no. 4; pp. 1220 - 1225
Main Authors:	SURBONE, A, FORD, H. JR, KELLEY, J. A, BEN-BARUCH, N, THOMAS, R. V, FINE, R, COWAN, K. H
Format:	Journal Article
Language:	English
Published:	Philadelphia, PA American Association for Cancer Research 15-02-1990
Subjects:	Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Azacitidine - administration & dosage Azacitidine - adverse effects Azacitidine - pharmacokinetics Azacitidine - therapeutic use Biological and medical sciences Chemotherapy Clinical Trials as Topic Drug Administration Schedule Drug Evaluation Female Humans Leukopenia - chemically induced Male Medical sciences Middle Aged Neoplasms - blood Neoplasms - drug therapy Neutropenia - chemically induced Pharmacology. Drug treatments Thrombocytopenia - chemically induced Antineoplastic agent Therapeutic efficiency Human Refractory Chemotherapy Treatment Intravenous administration Phase I trial Tumor Effective dose Malignant tumor Pharmacokinetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!